Inactive Instrument

News Hemispherx BioPharma, Inc Nyse

Equities

US42366C1036

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 10	AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	CI
Apr. 02	Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Apr. 25	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Apr. 18	GL
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	Apr. 15	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Apr. 11	GL
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	Apr. 10	GL
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	Apr. 10	CI
Challenges To Advance Notice Bylaws Are Spiking	Apr. 08	AQ
Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024	Apr. 02
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Apr. 02	GL
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference	Mar. 28	GL
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	Mar. 26	GL
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	Mar. 26	AQ
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Mar. 25	AQ
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	Mar. 25	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Mar. 22	GL
Transcript : AIM ImmunoTech Inc. - Special Call	Mar. 20
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Mar. 20	GL
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	Mar. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Hemispherx BioPharma, Inc Nyse

Equities

US42366C1036

Summary

Filters